

PRODUCT
CANDIDATE:
MOB-015

c\$91M
Annual Canadian market
for Onychomycosis

Current Market has only one
main product player

**Significant opportunity for
market disruption**

Sources:
IQVIA CompuScript Dec 2023 MAT

cipher[™]
PHARMACEUTICALS

Acquired marketing
rights from:

Moberg Pharma AB (OMX:MOB)



Indication:

Onychomycosis (Nail fungus)

Advantage:

Topical application, improved safety profile, once weekly
treatment

Regulatory next step:

EU: Product approved, July 2023
US: Pivotal Phase III study underway, enrollment completed

Timeline:

US: Pivotal Phase III study results expected January 2025

